Product Description
Eli Lilly is developing LY-3372993 as a treatment for Alzheimer Disease. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04451408)
Mechanisms of Action: AB Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Canada, China, Colombia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alzheimer Disease|Cognitive Dysfunction
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06653153 |
TRAILRUNNER-ALZ 3 | P3 |
Active, not recruiting |
Alzheimer Disease |
2029-04-01 |
2025-10-17 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05463731 |
TRAILRUNNER-ALZ 1 | P3 |
Completed |
Cognitive Dysfunction|Alzheimer Disease |
2024-04-24 |
2026-05-23 |
Primary Endpoints |
|
NCT04451408 |
J1G-MC-LAKB | P1 |
Completed |
Alzheimer Disease |
2024-11-18 |
2025-03-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
jRCT2031210492 |
jRCT2031210492 | P1 |
Active, not recruiting |
Alzheimer Disease |
2023-11-30 |
|||
CTR20260129 |
CTR20260129 | P1 |
Active, not recruiting |
Alzheimer Disease |
None |
2026-04-23 |
Start Date|Treatments|Trial Status |
|
NCT05552157 |
DIAN-TU | P3 |
Recruiting |
Alzheimer Disease |
2034-03-30 |
43% |
2025-11-13 |
|
NCT06647498 |
DIAN-TU-002 | P3 |
Recruiting |
Alzheimer Disease |
2034-03-01 |
40% |
2024-11-28 |
Primary Endpoints|Start Date |
2024-515656-20-00 |
J1G-MC-LAKI | P3 |
Recruiting |
Alzheimer Disease |
2031-01-23 |
2025-05-02 |
Treatments |
|
NCT07346495 |
J1G-GH-LAKE | P1 |
Active, not recruiting |
Healthy Volunteers |
2026-08-01 |
50% |
2026-04-23 |
|
jRCT2031220471 |
jRCT2031220471 | P3 |
Recruiting |
Alzheimer Disease |
2025-05-31 |
|||
NCT07056309 |
J1G-MC-LAKG | P1 |
Completed |
Healthy Volunteers |
2025-12-15 |
2026-01-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|